Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BIOCND Inc., Genor Biopharma deal

Genor granted BIOCND development rights to two mAbs. Genor granted BIOCND rights to GB232, an adalimumab biosimilar, in South,

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE